02.01.2019 14:43:28
|
Sarepta Enters Strategic Relationship With Aldevron For Supply Of Plasmid DNA
(RTTNews) - Sarepta Therapeutics, Inc. (SRPT) announced a long-term strategic relationship for the supply of plasmid DNA to fulfill Sarepta's needs for its gene therapy clinical trials and commercial supply. Aldevron will provide GMP-grade plasmid for Sarepta's micro-dystrophin Duchenne muscular dystrophy gene therapy program and Limb-girdle muscular dystrophy programs, as well as plasmid source material for future gene therapy programs.
Aldevron supplies plasmid DNA and gene editing enzymes to biopharmaceutical researchers developing advanced gene-based medicines. The company employs a team of 270 across its three locations in Fargo, North Dakota, Madison, Wisconsin, and Freiburg, Germany.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Sarepta Therapeutics Inc.mehr Nachrichten
05.11.24 |
Ausblick: Sarepta Therapeutics präsentiert Quartalsergebnisse (finanzen.net) |
Analysen zu Sarepta Therapeutics Inc.mehr Analysen
Aktien in diesem Artikel
Sarepta Therapeutics Inc. | 88,54 | -0,61% |
|